It was a pleasure to meet with Prof. Xavier Montalban (Multiple Sclerosis Centre of Catalonia, Vall d’Hebron, Barcelona Hospital Campus, Spain) to discuss the phase 3b STHENOS study, investigating the use of ofatumumab as a treatment option for relapsing multiple sclerosis.
The abstract entitled: ‘Effectiveness and Tolerability of Ofatumumab Versus First-line DMTs in Early RMS Patients: Phase 3b STHENOS Study Design’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021.
- What are the objectives of the STENOS study? (0:13)
- Could you give us a brief overview of the study design? (1:13)
- What are the primary and secondary outcome measures of the study? (1:46)
Disclosures: Xavier Montalban has received speaking honoraria and/or travel expenses for participation in scientific meetings, and/or has been a steering committee member of clinical trials and/or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of the EAN Congress, Virtual 2021
Share this Video
Related Videos In Multiple Sclerosis
Bernhard Hemmer, ECTRIMS 2021: Phase 3 Antelope Study Results Investigating Natalizumab Biosimilar PB006 in RMS
touchNEUROLOGY met up with Prof. Bernhard Hemmer (TUM-Klinikum rechts der Isar, Munich, Germany) to discuss the primary data from the phase III Antelope study, investigating proposed natalizumab biosimilar PB006 in relapsing remitting multiple sclerosis. The abstract entitled: ‘Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri® in patients with relapsing remitting multiple sclerosis: primary […]
Le Hanh Hua, ECTRIMS 2021: Hot Topics in Multiple Sclerosis
touchNEUROLOGY joins Dr Le Hanh Hua (Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA) to discuss the hot topics in the field of multiple sclerosis. The abstract entitled: ‘Safety and efficacy of siponimod in patients with active secondary progressive multiple sclerosis identifying as Hispanic from the phase 3 EXPAND study’ was […]
Le Hanh Hua, ECTRIMS 2021: Siponimod’s Efficacy on Secondary Progressive MS – Post-hoc Analysis of the EXPAND Study
It was a pleasure to meet with Dr Le Hanh Hua (Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA) to discuss the use of siponimod in patients with active secondary progressive multiple sclerosis identifying as Hispanic from the phase 3 EXPAND study. The abstract entitled: ‘Safety and efficacy of siponimod in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!